

1 Running head: **Body composition and training after stroke**

2 **Body composition and physical function after progressive**
3 **resistance and balance training among older adults after stroke**
4

5 **Birgit Vahlberg**¹, RPT, MSc; **Birgitta Lindmark**¹, RPT, PhD, Professor; **Lena**
6 **Zetterberg**¹, RPT, PhD; **Karin Hellström**¹, RPT, Ass Prof; and **Tommy Cederholm**²,
7 MD, PhD, Professor

8 ¹Department of Neuroscience, Physiotherapy, ²Department of Public Health and Caring
9 Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden

10 **Disclosures:** None

11 **Corresponding author:** Birgit Vahlberg

12 Address: Department of Neuroscience, Physiotherapy, Uppsala University, Box 593,
13 BMC, S-751 24 Uppsala, Sweden

14 Telephone: +4618 4714778

15 E-mail: Birgit.Vahlberg@neuro.uu.se

16 Birgitta.Lindmark@neuro.uu.se, Lena.Zetterberg@neuro.uu.se

17 Karin.Hellstrom@neuro.uu.se, Tommy.Cederholm@pubcare.uu.se

18

19

20

21 Word count text: 2800

22 Word count abstract: 243

23 Tables and figures 4

24 Clinical trial registration information: URL: <http://www.clinicaltrials.gov>. Unique
25 identifier: NCT1161329

26 **Abstract**

27 **Purpose:** To study the effects of a progressive resistance and balance (PRB) exercise
28 program on body composition with regard to its associations with physical function
29 among individuals approximately one year after stroke.

30 **Method:** A total of 43 individuals from the community (age 73 years (SD 5.0), 73%
31 men) were randomly assigned either to an intervention group (IG, $n=20$) that received a
32 PRB exercise program twice weekly for three months or a control group (CG, $n=23$). The
33 primary objectives were to correlate potential changes in the fat-free mass (FFM (kg) and
34 FFM index (FFMI) (kg/m^2), and fat-mass (FM (kg), (%) of body weight, FMI (kg/m^2)),
35 as measured by bioelectrical impedance analyses (Tanita®), with physical function,
36 including walking capacity; i.e., the 6 Min Walk Test; 6MWT, balance and mobility.

37 **Results:** At three months, a complete case analyses revealed a significant reduction in fat
38 mass per cent in the intervention group when compared with the control group; -1.5 vs.
39 0.13 % respectively; effect size, $ES=0.62$ standard error (SE), 0.80; $P=0.039$). No
40 between-group differences in FFM were observed. There was a between-group difference
41 in the 6MWT (25 vs. -10 m) at three months in favor of the IG ($r=0.47$, $P=0.04$). Changes
42 in FMI were associated with improved walking capacity in the IG.

43 **Conclusions:** Three months of PRB training might reduce fat mass in older adults
44 approximately one year after stroke. This exploratory study indicated an association
45 between improvements in physical performance and changes in body fat mass.

46

47

48 **Keywords:** body composition, functional performance, stroke, elderly

1 **BACKGROUND**

2 Muscle wasting might contribute to reduced muscle strength, i.e. sarcopenia, that may
3 affect balance and walking capacities of elderly patients after stroke [1, 2]. Muscle
4 abnormalities are common after hemiparetic stroke, and a specific type of stroke-induced
5 sarcopenia has been proposed [2]. Long-term muscle changes in combination with the
6 reduction of the fiber cross-sectional area and increased intramuscular fat deposition
7 emerges up to 6 months after stroke in all extremities [2-4]. Muscle wasting might also be
8 associated with increased fat mass (FM) [5], a state known as sarcopenic obesity [6]. A
9 significant increase in whole body FM one year after stroke was recently reported [5].
10 Sarcopenic obesity that is observed in up to 10% of individuals older than 80 years [6]
11 confers a major health risk, and features functional limitations and metabolic
12 dysregulations [6].

13 --To prevent disability and improve lipid and glucose metabolism after stroke, exercise
14 interventions might be useful [7, 8]. The control of cardio-metabolic risk factors, such as
15 the levels of high- and low-density lipoprotein cholesterol (HDLs and LDLs,
16 respectively), is usually considered insufficient after stroke [9]. Moderately intense
17 physical activity can reduce the risk for additional cardiovascular incidents and increase
18 mobility [10, 11]. Resistance training can increase muscle mass. Muscle contractions
19 increase glucose uptake and improve insulin sensitivity in muscle cells, and likely
20 improve the plasma lipoprotein profile [12]. We showed, in a recent study of a
21 progressive resistance and balance (PRB) exercise program, improvements in walking
22 capacity, walking speed and balance among a post-stroke population (Vahlberg,
23 submitted). However, there is a lack of data on the effects of PRB training on body
24 composition and cardio-metabolic risk factors, especially beyond the convalescent period
25 [7].

26 --The aims of the current explorative study were to (1) investigate whether a program of
27 PRB exercise could increase muscle mass, reduce FM, and affect cardio-metabolic risk
28 markers and indicators of growth and nutrition among elderly participants one year after
29 stroke; and (2) evaluate whether changes in physical function are correlated with changes
30 in body composition.

31 **METHODS**

32 **Participants**

33 Data were recently reported on a single-blind randomized controlled trial that examined
34 the outcome of a PRB exercise program for individuals with chronic stroke (Vahlberg,
35 submitted). Briefly, potential study participants aged 65 to 85 years were identified and
36 recruited after reviewing the Swedish quality discharge register (RIKS-stroke) at Uppsala
37 University Hospital. The eligibility criteria are presented elsewhere (Vahlberg,
38 submitted). In the current study, participants with pacemakers or systolic blood pressure
39 levels >180 mmHg as well as those who were unable to perform a bioelectric impedance
40 analysis (for any reason) were excluded; see the flow chart in Figure 1.

41 **Study design**

42 This was a 3-month randomized controlled study. One independent assessor, i.e. an
43 experienced physiotherapist who was blinded to the participant allocation, conducted the
44 measurements prior to the start of the intervention and at three months. The data were
45 collected from October 2009 to April 2011.

46 **Randomization procedure**

47 A computer-generated printout was used to randomly assign the participants to one of
48 two groups. Participants were informed of group allocation after baseline assessment. A
49 senior researcher who was not involved in the assessments did the assignment.

50 **Intervention**

51 The intervention group (IG) (n=20) received PRB exercise training, and the control group
52 (CG) (n=23) was encouraged to not change their lifestyles. As previously described,
53 training was performed within circuit classes that were held twice weekly for three
54 months. These classes consisted of functional exercises that targeted improvements in
55 lower extremity functioning [13] (Vahlberg, submitted). After the circuit class ended, the
56 training group spoke with the physiotherapist for 20 minutes regarding physical activity
57 behavior and risk factor modifications (see supplementary data in Appendix 1 for
58 descriptions of the PRB exercise program and the group discussion). One or two
59 questions were asked at each session from an individualized perspective. Identified
60 activity goals resulted in one tailored home exercise (to be performed daily) with the
61 intention to support participation in the PRB exercise training and increasing the level of
62 physical activity. The progression of the home training was evaluated weekly.

63

64 **Measurements**

65 Body composition, i.e., the fat-free mass index (FFMI, kg/m²), fat-mass index (FMI,
66 kg/m²) and the relative fat mass in percent of body weight (FM%), was measured as
67 previously described by bioelectrical impedance analysis (BIA; Tanita®, Vahlberg,
68 submitted). Sarcopenic obesity was defined accordingly; i.e., an FFMI below the 25th
69 percentile and an FMI above the 50th percentile of a Swiss reference population [14].
70 Body weight and height were measured while the participants wore light indoor clothing
71 and no shoes. BMI was calculated as weight (kg) divided by height (m) squared. BMI
72 values ≥ 30 kg/m² were used to indicate obesity. FM% above the suggested reference
73 values; i.e., 20% in men and 30% in women, were also used to indicate obesity [15].

74 --Total cholesterol as well as LDL and HDL cholesterol were analyzed as cardio-
75 metabolic risk markers. Serum insulin-like growth factor-I (IGF-1), plasma albumin, and
76 C-reactive protein (CRP) were analyzed as indicators of nutritional status and on-going
77 inflammation.

78 --Supine blood pressures were measured manually under standardized conditions at
79 baseline and at 3 months. Normal blood pressure was categorized as systolic values ≤ 139
80 or diastolic values ≤ 89 mm Hg.

81 --In this study, the cardiovascular disease risk score (CRS; a cumulative score where
82 higher scores denote greater risks of future cardiovascular events) was calculated at base-
83 line and after three months using a prediction algorithm based on age, resting blood
84 pressure, smoking status at the time of stroke, diabetic status, total cholesterol and HDL
85 [17]. Smoking status and diabetes were considered unchanged at three months. High CRS
86 score (e.g. a 10 year increased risk of a cardiovascular disease risk $> 20\%$) require
87 stronger risk factor modification. This model has also been used among individuals with
88 stroke and transient ischemic attack (TIA) to evaluate the effect of using a cardiac model
89 of rehabilitation [9, 18, 19].

90 --Physical function was measured as mobility (using the Short Physical Performance
91 Battery; SPPB) [20], balance (using the Berg Balance Scale; BBS) [21], walking capacity
92 (using the 6-Minute Walking Test; 6MWT) [22], and physical activity (using the Physical
93 Activity Scale for the Elderly; PASE) [23] as previously described (Vahlberg, submitted).
94 One item in the SPPB, i.e. time for five chair rise stands (s), was used to evaluate thigh

95 muscle strength [20]. The 6MWT measures participants' longest possible walking
96 distance at a usual pace over a 30 m course across 6 minutes [22]. The test was
97 standardized according to the recommendations of the American Thoracic Society [22].

98 --The Short Portable Mental Status Questionnaire (SPMSQ) was used to assess cognition.
99 SPMSQ consists of 10 questions and has a maximum score of 10 [24].

100 **Statistics, data analysis and ethical concerns**

101 In the original study (Vahlberg, submitted) a sample size of 67 individuals was
102 determined to be large enough to detect changes in balance (which was the primary
103 outcome for that study). Because the major objective of this study was to evaluate
104 whether potential improvements in physical function were related to changes in body
105 composition, no specific a priori power analyses were performed. This study should be
106 regarded as explorative, and its data might be useful for meta-analyses and for sample
107 size calculations.

108 --Statistical analyses are based on complete case analysis. Descriptive analyses were
109 performed based on the type and distribution of variables. To check for normal
110 distribution, the Shapiro-Wilk W test was used. Mean differences between the groups
111 were assessed using Student's t-test for continuous, normally distributed variables, and
112 the Mann-Whitney U test was applied for ordinal variables. Categorical variables were
113 compared using Pearson's chi-squared test (χ^2). To analyze within-group changes over
114 time, the paired-samples two-tailed t-test was performed for normally distributed
115 variables; otherwise, the Wilcoxon sign rank test was used. Cohen's d was used as a
116 measure of the within-group effect size. Correlation strength was calculated using
117 Spearman's rho. All analyses were examined using two-tailed test with a significance
118 level set at $P < 0.05$. All analyses were performed using SPSS version 19 (IBM, Armonk,
119 NY, USA).

120

121 **RESULTS**

122 A total of 43 individuals, 12 women and 31 men, could perform the BIA and were
123 included. Figure 1 summarizes the recruitment and participant flow. At baseline, no
124 significant between-group differences were noted with regard to the demographic data or
125 other measurements (Table 1). The median cognitive function was the maximum of 10
126 points at baseline (IQR range 7-10 p). The median attendance rate for the exercise classes

127 of the IG was 91%. No adverse events occurred during exercise. All individuals in the IG
128 wore a weighted belt while exercising, with a mean weight increase of 2.6 kg over the
129 exercise period. All of the participants were able to perform the given exercises.

130 **Effects by exercise on body composition**

131 FFM did not change in any group over the observation period. However, fat mass
132 percentage (FM%) showed a significant decrease in the IG group at three months, i.e. -
133 1.5 vs 0.13 % in the CG, ES=0.56, $P=0.023$. FM decreased by 1.47 kg in the IG, but this
134 decrease was not significantly different compared to the CG. As described previously, the
135 6MWT distance significantly improved for the IG after three months compared with the
136 CG (25 vs. -10 m, respectively, ES=0.69, $P=0.039$). At baseline, the prevalence of
137 sarcopenic obesity was 9% (4/43), i.e. two in each group. At three months still the two
138 individuals in the CG, but none in the IG, displayed sarcopenic obesity.

139 --A significant correlation was observed in the IG between changes in the 6MWT and
140 changes in the FMI ($r=0.47$, $P=0.04$), the FM percentage ($r=0.48$, $P=0.038$) and the FM
141 ($r=0.47$, $P=0.041$) after the PRB exercising for three months. A similar correlation could
142 not be observed when all study participants were combined (data not shown).

143 **Effects on cardio-metabolic risk**

144 The CRSs were high for both sexes and groups; at baseline, the median score was 24 ± 3
145 indicating an increased risk by >30% (to have a cardiovascular event in 10 years) in both
146 men and women. No reductions in CRSs (median change 0) or blood pressure were
147 observed within or between groups at three months. Table 3 shows that there were no
148 significant between-group changes in total cholesterol, HDL or LDL cholesterol. Serum
149 IGF-1 decreased in the IG (-12 vs. 4 $\mu\text{g/l}$, ES= 0.62, $P=0.019$) compared with the CG,
150 whereas serum levels of CRP and albumin were stable (Table 3).

151 **DISCUSSION**

152 Our findings suggest that PRB exercise among chronic stroke patients for three months
153 reduce FM, whereas there were no effects in FFM. As previously reported, improvements
154 were observed in walking capacity after training. However, this improvement (in this
155 cohort of post-stroke older individuals) was most likely not conferred by changes in
156 muscle mass. Interestingly, the improvement was rather associated with the reduction in
157 FM. As previously reported, muscle function might be improved regardless of changes in

158 its mass [1]. Muscle strength and power are determined by many factors except the mass
159 of myofibrillar proteins. Oxygenation, cellular fitness, nutrition, substrate availability, fat
160 infiltration of the muscle, inflammation, or endocrine status are some examples [25]. It is
161 difficult to speculate over which specific factor(s) that mediated the effect in this study
162 group. Nevertheless, muscle mass is important for mobility and strength as well as for
163 energy, lipid and glucose metabolism [26].

164 --Despite weight loading, half of the exercises employed by the IG in the current study
165 were mainly directed toward improving balance and less so at gaining muscle mass and
166 strength. Balance exercises are important and recommended because falls, fear of falling
167 and balance limitations are common among older individuals post-stroke and can lead to
168 reduced functional capacity during daily activities [28, 29].

169 --At baseline, IGF-1 levels were within the given reference values for both groups. A
170 decrease in IGF-1 was observed in the IG at three months. This finding was somewhat
171 unexpected because resistance training usually stimulates IGF-1 production, which might
172 be beneficial for muscle anabolism [30]. In obese, older sedentary individuals one year
173 after stroke, however, a decrease of IGF-1 after training might rather be a reflection of an
174 improved insulin sensitivity due to reduced FM [31]. We were unable to detect between-
175 group differences regarding changes in total cholesterol, HDL or LDL cholesterol. In
176 contrast to a previous study, the CRSs in the present study were not significantly reduced
177 within or between groups at three months [9]. However, the risk scores in the current
178 sample revealed a $\geq 20\%$ increased risk for future cardiovascular events [17]. Changes in
179 the cardio-metabolic risk markers among the IG were similar to studies reporting on the
180 effects of cardiac rehabilitation programs featuring aerobic exercise in combination with
181 lifestyle counseling after stroke or TIA [19, 32].

182 --At baseline, the prevalence of sarcopenic obesity was approximately 9%. Considering
183 the type of study group this is an unexpectedly low figure, which may indicate that the
184 study group is selected among fairly healthy and active individuals that have had a
185 previous stroke. Still, the mean PASE score was 98 ± 65 which is approximately 61% of
186 that in a healthy population [33]. Sarcopenic obesity usually reflects a combination of
187 low levels of physical activity and a relatively high energy intake. Interestingly,
188 sarcopenic obesity was no longer present in the IG after PRB exercising.

189 --In the current study, exercise intensity was related to the individual's capacity and
190 performed with low-to-moderate intensity with >10 repetitions of each exercise, for
191 example progressively increasing the number of weight lifts [12]. This protocol
192 corresponds to approximately 50-70% of the one-repetition maximum [12]. High
193 intensity exercise among older individuals improves lower-limb strength more than low
194 intensity exercise; however, it might not be required to improve functional performance
195 [34]. The exercise intensity in the current study should have been high enough to induce
196 increases in fat-free mass.

197 --The current study has limitations that need to be addressed. This exploratory study was
198 not based on sample size calculation regarding the main objectives of these post-hoc
199 analyses, thus it might have been underpowered with risk of type II errors. Furthermore,
200 the Hawthorn effect must be considered, meaning that the individuals in the CG might
201 have started to exercise although not encouraged to do so. In addition, self-reports of
202 physical activity might not be considered an accurate measurement compared with
203 accelerometers [35]. Self-reports of physical activity (e.g., the PASE) tend to
204 overestimate physical activity [23]. The strengths of this study are its randomized
205 controlled design, the predefined exercise protocol and the limited age range of
206 participants.

207 --In conclusion, the findings of this exploratory pilot study indicate that improved
208 walking capacity induced by a PRB exercise program among older adults after stroke was
209 associated with a decrease in fat mass, but not an increase in muscle mass. The reduction
210 of fat mass might have caused reduced IGF-1, possibly indicating improved insulin
211 sensitivity. Additional studies are needed to investigate both short-term and long-term
212 exercise treatment effects on body composition in post-stroke patients, in order to further
213 elucidate the potential importance of changes in body composition, i.e. FFM and FM,
214 respectively, for improvements in physical function.

215 **Acknowledgements**

216 We would like to acknowledge Susanna Tuvemo Johnson, RPT, MSc at Uppsala
217 University for support with the data collection. We would also like to thank the
218 physiotherapists, the assistants, and all individuals affected by stroke who participated in
219 the progressive resistance and balance exercise program.

220

221 **CONFLICTS OF INTEREST**

222 The authors declare no conflicts of interest

223 -Insert Appendix 1 about here-

224

225

- 227 [1] A. J. Cruz-Jentoft, J. P. Baeyens, J. M. Bauer, Y. Boirie, T. Cederholm, F. Landi, *et al.*,
228 "Sarcopenia: European consensus on definition and diagnosis: Report of the European
229 Working Group on Sarcopenia in Older People," *Age Ageing*, vol. 39, pp. 412-23, Jul
230 2010.
- 231 [2] N. Scherbakov, S. von Haehling, S. D. Anker, U. Dirnagl, and W. Doehner, "Stroke
232 induced Sarcopenia: muscle wasting and disability after stroke," *Int J Cardiol*, vol. 170,
233 pp. 89-94, Dec 2013.
- 234 [3] L. Jørgensen and B. K. Jacobsen, "Changes in muscle mass, fat mass, and bone mineral
235 content in the legs after stroke: a 1 year prospective study," *Bone*, vol. 28, pp. 655-9, Jun
236 2001.
- 237 [4] G. Carin-Levy, C. Greig, A. Young, S. Lewis, J. Hannan, and G. Mead, "Longitudinal
238 changes in muscle strength and mass after acute stroke.," *Cerebrovasc Dis*, vol. 21, pp.
239 201-7, 2006.
- 240 [5] C. English, K. Thoirs, A. Coates, A. Ryan, and J. Bernhardt, "Changes in fat mass in stroke
241 survivors: a systematic review," *Int J Stroke*, vol. 7, pp. 491-8, Aug 2012.
- 242 [6] M. Zamboni, G. Mazzali, F. Fantin, A. Rossi, and V. Di Francesco, "Sarcopenic obesity: a
243 new category of obesity in the elderly.," *Nutr Metab Cardiovasc Dis*, vol. 18, pp. 388-95,
244 Jun 2008.
- 245 [7] D. H. Saunders, M. Sanderson, M. Brazzelli, C. A. Greig, and G. E. Mead, "Physical fitness
246 training for stroke patients," *Cochrane Database Syst Rev*, vol. 10, p. CD003316, 2013.
- 247 [8] G. R. Hunter, J. P. McCarthy, and M. M. Bamman, "Effects of resistance training on older
248 adults," *Sports Med*, vol. 34, pp. 329-48, 2004.
- 249 [9] M. Mackay-Lyons, M. Thornton, T. Ruggles, and M. Che, "Non-pharmacological
250 interventions for preventing secondary vascular events after stroke or transient
251 ischemic attack," *Cochrane Database Syst Rev*, vol. 3, p. CD008656, 2013.
- 252 [10] G. C. Wendel-Vos, A. J. Schuit, E. J. Feskens, H. C. Boshuizen, W. M. Verschuren, W. H.
253 Saris, *et al.*, "Physical activity and stroke. A meta-analysis of observational data.," *Int J*
254 *Epidemiol*, vol. 33, pp. 787-98, Aug 2004.
- 255 [11] C. K. Liu, X. Leng, F. C. Hsu, S. B. Kritchevsky, J. Ding, C. P. Earnest, *et al.*, "The impact of
256 sarcopenia on a physical activity intervention: the Lifestyle Interventions and
257 Independence for Elders Pilot Study (LIFE-P)," *J Nutr Health Aging*, vol. 18, pp. 59-64, Jan
258 2014.
- 259 [12] M. A. Williams, W. L. Haskell, P. A. Ades, E. A. Amsterdam, V. Bittner, B. A. Franklin, *et*
260 *al.*, "Resistance exercise in individuals with and without cardiovascular disease: 2007
261 update: a scientific statement from the American Heart Association Council on Clinical
262 Cardiology and Council on Nutrition, Physical Activity, and Metabolism," *Circulation*, vol.
263 116, pp. 572-84, Jul 2007.
- 264 [13] E. Rosendahl, Y. Gustafson, E. Nordin, L. Lundin-Olsson, and L. Nyberg, "A randomized
265 controlled trial of fall prevention by a high-intensity functional exercise program for
266 older people living in residential care facilities.," *Aging Clin Exp Res*, vol. 20, pp. 67-75,
267 Feb 2008.
- 268 [14] Y. Schutz, U. U. Kyle, and C. Pichard, "Fat-free mass index and fat mass index percentiles
269 in Caucasians aged 18-98 y.," *Int J Obes Relat Metab Disord*, vol. 26, pp. 953-60, Jul
270 2002.
- 271 [15] R. N. Baumgartner, "Body composition in healthy aging," *Ann N Y Acad Sci*, vol. 904, pp.
272 437-48, May 2000.
- 273 [16] "The fifth report of the Joint National Committee on Detection, Evaluation, and
274 Treatment of High Blood Pressure (JNC V)," *Arch Intern Med*, vol. 153, pp. 154-83, Jan
275 1993.

- 276 [17] R. B. D'Agostino, R. S. Vasan, M. J. Pencina, P. A. Wolf, M. Cobain, J. M. Massaro, *et al.*,
277 "General cardiovascular risk profile for use in primary care: the Framingham Heart
278 Study," *Circulation*, vol. 117, pp. 743-53, Feb 2008.
- 279 [18] O. Lennon, A. Carey, N. Gaffney, J. Stephenson, and C. Blake, "A pilot randomized
280 controlled trial to evaluate the benefit of the cardiac rehabilitation paradigm for the
281 non-acute ischaemic stroke population," *Clin Rehabil*, vol. 22, pp. 125-33, Feb 2008.
- 282 [19] H. Kirk, P. Kersten, P. Crawford, A. Keens, A. Ashburn, and J. Conway, "The cardiac model
283 of rehabilitation for reducing cardiovascular risk factors post transient ischaemic attack
284 and stroke: a randomized controlled trial," *Clin Rehabil*, vol. 28, pp. 339-49, Apr 2014.
- 285 [20] J. M. Guralnik, L. Ferrucci, E. M. Simonsick, M. E. Salive, and R. B. Wallace, "Lower-
286 extremity function in persons over the age of 70 years as a predictor of subsequent
287 disability.," *N Engl J Med*, vol. 332, pp. 556-61, Mar 1995.
- 288 [21] K. Berg, S. Wood-Dauphinee, and J. I. Williams, "The Balance Scale: reliability assessment
289 with elderly residents and patients with an acute stroke.," *Scand J Rehabil Med*, vol. 27,
290 pp. 27-36, Mar 1995.
- 291 [22] "ATS statement: guidelines for the six-minute walk test.," *Am J Respir Crit Care Med*, vol.
292 166, pp. 111-7, Jul 2002.
- 293 [23] R. A. Washburn, K. W. Smith, A. M. Jette, and C. A. Janney, "The Physical Activity Scale
294 for the Elderly (PASE): development and evaluation.," *J Clin Epidemiol*, vol. 46, pp. 153-
295 62, Feb 1993.
- 296 [24] Pfeiffer, "A short portable mental status questionnaire for the assessment of organic
297 brain deficit in elderly patients.," *J am geriatr soc*, vol. 23, pp. 433-441, 1975.
- 298 [25] A. J. Cruz-Jentoft, F. Landi, E. Topinková, and J. P. Michel, "Understanding sarcopenia as
299 a geriatric syndrome.," *Curr Opin Clin Nutr Metab Care*, vol. 13, pp. 1-7, Jan 2010.
- 300 [26] G. Biolo, T. Cederholm, and M. Muscaritoli, "Muscle contractile and metabolic
301 dysfunction is a common feature of sarcopenia of aging and chronic diseases: From
302 sarcopenic obesity to cachexia," *Clin Nutr*, Mar 2014.
- 303 [27] M. J. Lee, S. L. Kilbreath, M. F. Singh, B. Zeman, and G. M. Davis, "Effect of progressive
304 resistance training on muscle performance after chronic stroke," *Med Sci Sports Exerc*,
305 vol. 42, pp. 23-34, Jan 2010.
- 306 [28] B. Vahlberg, T. Cederholm, B. Lindmark, L. Zetterberg, and K. Hellström, "Factors Related
307 to Performance-Based Mobility and Self-reported Physical Activity in Individuals 1-3
308 Years after Stroke: A Cross-sectional Cohort Study," *J Stroke Cerebrovasc Dis*, May 2013.
- 309 [29] A. C. o. S. Medicine, "American College of Sports Medicine position stand. Progression
310 models in resistance training for healthy adults," *Med Sci Sports Exerc*, vol. 41, pp. 687-
311 708, Mar 2009.
- 312 [30] G. Goldspink, "Age-related loss of muscle mass and strength," *J Aging Res*, vol. 2012, p.
313 158279, 2012.
- 314 [31] N. Friedrich, B. Thuesen, T. Jørgensen, A. Juul, C. Spielhagen, H. Wallaschofski, *et al.*,
315 "The association between IGF-I and insulin resistance: a general population study in
316 Danish adults," *Diabetes Care*, vol. 35, pp. 768-73, Apr 2012.
- 317 [32] O. Lennon, R. Galvin, K. Smith, C. Doody, and C. Blake, "Lifestyle interventions for
318 secondary disease prevention in stroke and transient ischaemic attack: a systematic
319 review," *Eur J Prev Cardiol*, Mar 2013.
- 320 [33] A. Danielsson, C. Meirelles, C. Willen, and K. S. Sunnerhagen, "Physical Activity in
321 Community-Dwelling Stroke Survivors and a Healthy Population Is Not Explained
322 by Motor Function Only," *PM R*, Aug 2013.
- 323 [34] M. J. Raymond, R. E. Bramley-Tzerefos, K. J. Jeffs, A. Winter, and A. E. Holland,
324 "Systematic review of high-intensity progressive resistance strength training of the
325 lower limb compared with other intensities of strength training in older adults," *Arch*
326 *Phys Med Rehabil*, vol. 94, pp. 1458-72, Aug 2013.

327 [35] R. A. Washburn and J. L. Ficker, "Physical Activity Scale for the Elderly (PASE): the
328 relationship with activity measured by a portable accelerometer," *J Sports Med Phys*
329 *Fitness*, vol. 39, pp. 336-40, Dec 1999.

330

331 **FIGURE LEGEND:**

332 **Figure 1.** Flow chart of the participants

333

334

335

336

337

338

339

340

341

342

343

344

345

346


347 Abbreviations: BIA, bioelectric impedance analysis; CG, control group; IG, intervention

348 group

349

350

351



352 **Table 1.** Baseline demographic and clinical characteristics of individuals approximately
 353 one year after stroke who were allocated to the intervention (IG) or control group (CG).

Characteristic	IG (n=20)	CG (n=23)	P-value
Men, n (%)	17 (81)	16 (67)	0.3
Age (years), mean (SD)	72.7 (5.5)	73.7 (5.4)	0.4
Time (months) since stroke onset, median (IQR)	14 (4)	14 (3)	
BMI, kg/m ² , n (%)			0.26
<22 (moderate underweight)			
22-29.9 (normal/overweight)	15 (71)	14 (58)	
>30 (obese)	6 (29)	10 (42)	
Blood pressure:			
SBP, median (IQR)	145(23)	145 (24)	0.9
DBP, median (IQR)	85 (10)	75 (10)	0.07
Cerebral infarction	17 (81)	20 (83)	0.8
Intra-cerebral hemorrhage	4 (19)	4 (17)	0.8
CRS, median (IQR)	24 (3)	24 (1)	0.6
CCI, n (%)			0.6
0	11 (52.4)	13 (54.2)	0.9
1	6 (28.6)	8 (33.3)	0.7
2	4 (19.0)	2 (8.3)	0.4
3	0	1 (4.2)	0.1
Risk factors for stroke, n (%)	n=19	n=23	
Earlier stroke	4 (26.1)	6 (21.1)	0.5
TIA	1 (5.3)	5 (22.7)	0.2
Atrial fibrillation	3 (15.8)	4 (17.4)	0.6
Smoking	2 (11.1)	1 (4)	0.4
Hypertension	13 (68.4)	17 (73.9)	0.7
Diabetes	3 (15.8)	4 (17.4)	

354 Abbreviations: CCI, Charlson Comorbidity Index based on weighted conditions, 0-4;
 355 CG, control group; CRS, cardiovascular disease risk score; DBP, diastolic blood
 356 pressure; IG, intervention group; SBP, systolic blood pressure; TIA, transient ischemic
 357 attack
 358

Table 2. Within-group and between-group differences of body composition and physical function at the start of intervention and after 3 months*.

Assessment occasion	Intervention Group (n=20) Male (n=16), Female (n=4)				Control Group (n=23) Male (n=14), Female (n=8)				Difference Between Intervention – Control 3 months	
	Base-line	3-mo follow-up	Absolute Change	P- value	Base-line	3-mo follow-up	Absolute Change	P- value	Mean/Median difference in change (95% CI)	P- value
FFM, kg, median (IQR)										0.70
All individuals			-0.7 (7.8)	0.14			-1.1 (4.6)	0.18	0.50 (-2.0 to 4.2)	
Male	61.30 (11.1)	59.82 (7.6)	-0.80 (9.1)		56.20 (15.7)	56.5 (8.9)	-0.95 (3.0)			
Female	43.10 (14.2)	42.57 (3.7)	0.75 (6.6)		47.15 (3.8)	43.2 (7.0)	-2.60 (7.2)			
FFMI, kg/m², median (IQR)										
All individuals			0.26 (1.2)	0.53			0.02 (1.3)	0.93	-0.16 (-0.87 to 0.44)	0.53
Male	19.95 (2.6)	20.09 (2.3)	0.13 (1.4)		20.50 (3.2)	20.75 (2.0)	-0.16 (1.0)			
Female	16.83 (1.4)	17.11 (1.1)	0.44 (0.7)		17.8 (3.3)	17.51 (1.8)	0.06 (1.9)			
FM, kg, mean (SD)										
All individuals			-1.47 (2.6)	0.021			-0.019 (2.2)	0.97	1.45 (-0.5 to 2.94)	0.057
Male	23.96 (6.4)	22.30 (7.4)	-1.66 (2.8)		25.23 (7.1)	24.95 (6.2)	0.31 (2.2)			
Female	30.30 (5.7)	27.47 (7.0)	-0.69 (2.0)		33.80 (12.9)	33.21 (13.0)	-0.59 (2.2)			
FM%, mean (SD)										
All individuals			-1.50 (2.7)	0.023			0.13 (2.6)	0.80	1.63 (0.01 to 3.26)	0.048
Male	27.01 (4.9)	25.51 (5.9)	-1.51 (2.9)		28.52 (34.8)	28.22 (3.7)	0.41 (2.3)			
Female	39.68 (3.3)	37.57 (5.2)	-1.45 (2.3)		40.78 (8.7)	40.41 (9.0)	-0.38 (3.0)			
FMI, kg/m², mean (IQR)										
All individuals			-0.40 (0.9)	0.053			-0.20 (1.1)	0.38	0.20 (-0.41 to 0.81)	0.51
Male	7.55 (2.1)	7.11 (2.4)	-0.44 (0.9)		8.20 (2.2)	8.07 (1.9)	-0.18 (1.2)			
Female	11.07 (1.9)	10.58 (4.9)	-0.27 (0.8)		12.94 (8.4)	12.70 (5.2)	-0.24 (0.9)			
BMI, kg/m², mean (SD)				0.42				0.36	0.007 (-0.76 to 0.77)	1.0
All individuals			-0.23 (1.3)		29.07 (4.6)		-0.23 (1.2)			
Male	27.4 (6.0)	27.1 (3.3)	-0.34 (1.4)		28.3 (3.1)	28.2 (5.7)	-0.21 (1.4)	-0.21		
Female	28.4 (2.5)	27.9 (2.9)	0.24 (0.6)		30.6 (6.7)	30.3 (6.6)	-0.27 (0.6)	-0.27		
PASE (≥0 points) median (SD)	100 (72)	110 (85)	16 (74)	0.51	90 (86)	95 (79)	2 (108)	0.78	0.5(-34.0 to 36.0)	1.0
BBS (0-56 points), median (IQR)	51.5 (7)	53.5 (5)	1 (3)	0.013	52.5 (6)	52.0 (4)	1 (1)	0.34	-1 (-2 to 0)	0.2

6MWT (meters), median (SD)	390 (109)	420 (181)	25 (65)	0.067	395 (141)	385 (170)	-10 (45)	0.29	-25 (-55.0 to 0.0)	0.039
SPPB (0-12 points), median (IQR)	9 (5)	11(4)	0 (3)	0.25	9 (3)	10 (2)	0 (1)	0.12	0 (-1 to 1)	0.9
Chair rise (sec), median (IQR)	14.0 (6.1)	13.5(6.4)	0.5 (4.7)	0.78	17.0 (8.1)	15.0 (5.2)	0.05 (2.6)	0.64	-0.3 (-1.9 to 1.9)	0.7

*Data are presented as the means (SD) or medians (IQR) and 95% CIs based on the complete-case analysis. The Hodges-Lehmann test was used to estimate the median. P-values were obtained using non-parametric analyses for ordinal and not normal distributed data. The significance level was set at P<0.05.

Abbreviations: BBS, Bergs Balance Scale; BMI, Body Mass Index; CIs, confidence intervals; FFMI, fat-free mass index; FMI, fat-mass index; FM, fat mass; FM%, fat mass percent; PASE, Physical Activity Scale for the Elderly; 6MWT, Six-Minute Walking Test; SPPB, Short Physical Performance Test

Table 3. Within-group and Between-group differences of nutritional status and cardio-metabolic risk markers at the start of intervention and after 3 months*

Assessment occasion (mo)	Intervention Group			Control Group			Difference Between Intervention – Control 3 months	
	0 (n=20)	3 (n=18)	P-value	0 (n=24)	3 (n=21)	P-value	Median 95% CIs	P-value
Plasma albumin (g/l), median (IQR) Reference: >34 g/l	38.0 (3.8)	38.0 (4.2)	0.1	37.0 (2.5)	38.0(6.5)	0.4	2 (0 to 3)	0.09
Plasma total cholesterol , median (IQR) Reference: <5.0 mmol/l	4.7 (0.9)	4.2 (1.0)	0.09	4.7 (1.4)	4.6 (1.9)	0.2	0.1 (-0.3 to 0.6)	0.7
Plasma HDL cholesterol , median (IQR) Reference: >1.1 mmol/l in men, >1.2 mmol/l in women	1.2 (0.4)	1.2 (0.3)	0.06	1.2 (0.5)	1.2 (0.5)	0.2	0 (-0.1 to 0.1)	0.5
Plasma LDL cholesterol , median (IQR) Reference: <3 mmol/l	2.4 (0.7)	2.3 (0.6)	0.5	2.4 (1.4)	2.5 (0.9)	0.4	0.2 (-0.2 to 0.4)	0.3
Serum IGF-1* , median (IQR) Reference 64-188 µg/l	126 (48)	118 (43)	0.023	119 (51)	129 (61)	0.4	17.5(3 to 32)	0.019
Plasma CRP , median (IQR) Reference: <5.0 mg/l, median (IQR)	1.4 (2.0)	1.1 (2.6)	0.7	3.0 (6.2)	2.9 (6.5)	0.8	-0.07 (-2 to 1.02)	0.9

*Data are presented as medians (IQR) and 95% confidence intervals (CIs) based on the complete-case analysis. The Hodges-Lehmann test was used for median estimates. For non-normal variables, P-values were obtained using non-parametric analyses. The significance level was set at $P < 0.05$.

Abbreviations: CIs, confidence intervals; CRP, C-reactive protein; HDL, high density lipoprotein; IGF-1, insulin-like growth factor-1; LDL, low density lipoprotein. * Reference values according to the Department of Clinical Chemistry for individuals aged 71-75 years (based on the median age of this population).

Appendix : Descriptions of the progressive resistance and balance exercise program and the group discussion.

Warming up: Stationary cycling or walking

Progressive resistance and balance exercises:

Squat in a parallel or walking stance	A1
Body weight transfer in a parallel or walking stance	A2, A3
Standing up from sitting in parallel or walking stance	A4, A5
Side and forward lunge	A6, A7
Step-up	A8
Walking forward in tandem gait	B1
Walking in various directions	B2
Walking with turns	B3, B8
Walking over obstacles	B4
Step onto and over boxes	B5
Walking on a soft surface	B6

Questions concerning physical activity:

“What is a physical activity to you?”

“What are the barriers and facilitators for you to be physically active?”

“What reasons do you perceive for increasing your physical activity level in your daily life?”

“How ready are you to make changes to your physical activity level in the near future?”

“What pro and cons do you perceive with being physically active?”

“How much time do you spend sitting each day?”

“What are your future plans to be physically active?”

A: static (fixed base of support) and dynamic (changing base of support) balance exercises in combination with strength exercises

B: dynamic balance exercises while walking